多中心研究:放射影像-临床列线图预测不可切除肝细胞癌DEB-TACE与分子靶向药物序贯治疗的获益
本研究为回顾性多中心分析,纳入17家机构2018年6月至2022年12月接受DEB-TACE治疗的202例不可切除肝细胞癌患者,构建放射影像-临床列线图预测无进展生存期。肿瘤大小、BCLC分期和影像组学评分是独立危险因素,列线图预测6、12、18、24个月PFS的AUC分别为0.857、0.810、0.843、0.838,并可能有助于识别可从靶向序贯治疗中获益的患者。
要点
- 肿瘤大小、BCLC分期和Rad-score是DEB-TACE后PFS的独立危险因素。
- 放射影像-临床列线图预测PFS的6、12、18、24个月AUC分别为0.857、0.810、0.843、0.838。
- 基于该模型,BCLC-B和C期低风险患者PFS高于高风险患者(P=0.021)。
核心结论
- 放射影像-临床模型可能有助于预测不可切除肝细胞癌患者DEB-TACE后的PFS,并识别可能从靶向序贯治疗中获益的患者。
研究设计与样本
- 回顾性分析,纳入17家机构2018年6月至2022年12月接受DEB-TACE治疗的202例不可切除肝细胞癌患者;从患者中计算提取PFS相关影像组学特征,采用LASSO回归构建Rad-signature模型,再结合Rad-signature与临床变量通过Cox回归构建Rad-Clinical模型并以列线图呈现。
诊断标准与关键数值
- 肿瘤大小、BCLC分期和Rad-score为PFS独立危险因素,Rad-Clinical模型预测PFS的HR为2.08(95%CI 1.56-2.78,P<0.001);6、12、18、24个月AUC分别为0.857、0.810、0.843、0.838;较影像组学列线图和临床列线图,净重分类改善为45.2%(95%CI 0.260-0.632,P<0.05),综合判别改善为14.9%(95%CI 0.064-0.281,P<0.05)。
临床应用与阅片要点
- 基于该模型,BCLC-B和C期低风险患者PFS高于高风险患者(P=0.021);BCLC-B期高风险和低风险患者接受靶向序贯治疗均显示显著获益(P=0.018,P=0.012),而BCLC-C期高风险患者获益不大(P=0.052)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Exploring the efficacy of a Radiological-Clinical (Rad-Clinical) model in predicting prognosis of unresectable hepatocellular carcinoma (HCC) patients after drug eluting beads transcatheter arterial chemoembolization (DEB-TACE) to optimize the targeted sequential treatment.
METHODS: In this retrospective analysis, we included 202 patients with unresectable HCC who received DEB-TACE treatment in 17 institutions from June 2018 to December 2022. Progression-free survival (PFS)-related radiomics features were computationally extracted from HCC patients to build a radiological signature (Rad-signature) model with least absolute shrinkage and selection operator regression. A Rad-Clinical model for postoperative PFS was further constructed according to the Rad-signature and clinical variables by Cox regression analysis. It was presented as a nomogram and evaluated by receiver operating characteristic curves, calibration curves, and decision curve analysis. And further evaluate the application value of Rad-Clinical model in clinical stages and targeted sequential therapy of HCC.
RESULTS: Tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, and radiomics score (Rad-score) were found to be independent risk factors for PFS after DEB-TACE treatment for unresectable HCC, with the Rad-Clinical model being the greatest predictor of PFS in these patients (hazard ratio: 2.08; 95% confidence interval: 1.56-2.78; P < 0.001) along with high 6 months, 12 months, 18 months, and 24 months area under the curves of 0.857, 0.810, 0.843, and 0.838, respectively. In addition, compared to the radiomics and clinical nomograms, the Radiological-Clinical nomogram also significantly improved the classification accuracy for PFS outcomes, based on the net reclassification improvement (45.2%, 95% CI 0.260-0.632, p < 0.05) and integrated discrimination improvement (14.9%, 95% CI 0.064-0.281, p < 0.05). Based on this model, low-risk patients had higher PFS than high-risk patients in BCLC-B and C stages (P = 0.021). Targeted sequential therapy for patients with high and low-risk HCC in BCLC-B stage exhibited significant benefits (P = 0.018, P = 0.012), but patients with high-risk HCC in BCLC-C stage did not benefit much (P = 0.052).
CONCLUSION: The Rad-Clinical model may be favorable for predicting PFS in patients with unresectable HCC treated with DEB-TACE and for identifying patients who may benefit from targeted sequential therapy.
引用
- Liu K, Zheng X, Lu D, et al. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram. Radiol Med. 2023. PMID: 37863847. doi:10.1007/s11547-023-01736-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。